Fig 1: The effect of IL-1β on osteoclast-associated genes. (a) RANKL, (b) OPG and (c) RANKL/OPG ratio of HCEM. (d) RANKL, (e) OPG and (f) RANKL/OPG ratio of pHCB by semiquantitive RT-PCR (one-way ANOVA, Dunnett’s T3 post hoc test, *P<0.05; **P<0.01, n=4). ANOVA, analysis of variance; HCEM, human cementoblast cell line; IL, interleukin; OPG, osteoprotegerin; pHCB, primary human cementoblasts; RANKL, receptor activator of nuclear factor kappa-B ligand; RT-PCR, reverse transcriptase-polymerase chain reaction.
Fig 2: mRNA expression of cells collected from different fractions of enzymatic digestion of tooth. (a) BSP, DMP-1 and ALP expression. (b) IL-1 receptor 1 and receptor 2 expression. (c) RANKL and OPG expression after treatment with IL-1β (mixture: cells from 60–90 min fractions). ALP, alkaline phosphatase; BSP, bone sialoprotein; DMP-1, dentin matrix acidic phosphoprotein 1; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; HCEM, human cementoblast cell line; hPDL, primary human periodontal ligament cells; IL, interleukin; OPG, osteoprotegerin; pHCB, primary human cementoblasts; RANKL, receptor activator of nuclear factor kappa-B ligand.
Supplier Page from BioLegend for Recombinant Human TRANCE (RANKL) (carrier-free)